Overview
Open Interventions → Pulmonary vasodilators. Choose Off, Low, Medium, High. Effect levels and flow targets represent illustrative modeled responses; they are not clinical dose instructions.
Selexipag and its active metabolite selectively activate the IP receptor, increasing cAMP-dependent prostacyclin-pathway signaling. It is an oral IP agonist, not a prostacyclin analogue.
The paused reference covers the route (Oral maintenance treatment after individualized titration.), example doses/settings, indications, adverse effects, contraindications/precautions and monitoring. These details are available after the intervention is selected.
What to monitor in the reference: Tolerability, blood pressure, interactions, exercise capacity, biomarkers and RV function; confirm the local label before initiation or restart.